| Theme | Evidence-based strategies for secondary hyperparathyroidism | |
|---|---|---|
| Title | New predictable marker; FGF-23 for the stage of secondary hyperparathyroidism | |
| Publish Date | 2004/07 | |
| Author | Shohei Nakanishi | The Nephrology Center, Toranomon Hospital |
| Author | Masafumi Fukagawa | Division of Nephrology and Dialysis Center, Kobe University School of Medicine |
| [ Summary ] | It is important to choose the most suitable therapies for the stage of secondary hyperparathyroidism. FGF-23 was discoverd through analysis of hereditary diseases with hypophosphatemia and it is thought that FGF-23 is one of phosphatonin. It is possible to predict the prognosis for secondary hyperparathyroidism by serum FGF-23 levels. | |